High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
Shimazaki
C
C
Uchida
R
R
Nakano
S
S
Namura
K
K
Fuchida
S-i
SI
Okano
A
A
Okamoto
M
M
Inaba
T
T
D000469:Alkaline Phosphatase / Q000097:blood*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D011719:Pyrazines / Q000008:administration & dosage*; D016103:Spinal Fractures / Q000150:complications*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D000469:Alkaline Phosphatase